"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
--------------------------------------------------------------------
Source: Zero Hedge
Published: 2026-02-24 01:25 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Business, Law & Courts, Drugs
--------------------------------------------------------------------
Snippet:
Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound).
--------------------------------------------------------------------